Skip to content

CalAmp CAMP Debt-to-equity

Debt-to-equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
1.4×+1.1×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
0.0×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
0.0×
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
27.2×+26.1×
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
0.3×-0.8×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-0.3×

Other financials

Income statement

See full
Revenue$1.3M+50.8%
Operating income-$13.1M+0.2%
Net income-$18.3M-47.4%
EPS (diluted)-$0.32+48.4%

Balance sheet

See full
Cash & equivalents$100.8M+97.9%
Total debt$2.1M-73.2%
Total equity$30.9M-40.1%
Total assets$105.5M+68.0%

Cash flow

See full
Operating cash flow-$11.0M+23.1%
CapEx--100%
Free cash flow-$11.0M+24.6%

Valuation

See full
Market cap$226.92M+666%
Enterprise value$128.2M-3,860%
P/S57.7×+47.8×

Profitability

See full
Operating margin-1,335.2%-512pp
Net margin-2,193.7%-581pp
FCF margin-1,254%

Returns & leverage

See full
Return on equity-209.3%
Current ratio6.1×-1.9×

Where this comes from

Calculated from CalAmp’s reported figures.

Based on the most recent quarter.

The official record: CalAmp’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CalAmp's debt-to-equity?
CalAmp (CAMP) reported debt-to-equity of 0.1× in Q1 2026.
How has CalAmp's debt-to-equity changed year-over-year?
CalAmp's debt-to-equity decreased by 55.2% year-over-year, from 0.2× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.